Skip to main content

Table 4 Frequency of AEs based on causality assessment

From: Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

Causality

N (%)

Possible

786 (82.13)

Unlikely

141 (14.73)

Unassessable/unclassifiable

30 (3.13)

Total

957 (100)

  1. AE adverse event
Back to article page

Journal of Pharmaceutical Policy and Practice

ISSN: 2052-3211

Contact us